Core Points - Faruqi & Faruqi, LLP is investigating potential claims against SelectQuote, Inc. and reminds investors of the October 10, 2025 deadline to seek the role of lead plaintiff in a federal securities class action [2][3] Allegations Against SelectQuote - The complaint alleges that SelectQuote and its executives violated federal securities laws by making false and misleading statements, including directing Medicare beneficiaries to plans that compensated SelectQuote the most, rather than providing unbiased comparisons [4] - SelectQuote is accused of receiving illegal kickbacks from health insurance companies to steer Medicare beneficiaries towards certain plans, which led to non-compliance with applicable laws and regulations [4][5] - The U.S. Department of Justice filed a complaint against SelectQuote, alleging that from 2016 to at least 2021, the company received tens of millions of dollars in illegal kickbacks and engaged in discriminatory practices against less profitable beneficiaries [5] Stock Market Reaction - Following the DOJ's allegations, SelectQuote's stock price fell by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025, with unusually heavy trading volume [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against PubMatic, Inc. due to alleged violations of federal securities laws, encouraging affected investors to contact them for legal options [1][3]. Group 1: Allegations Against PubMatic - The complaint alleges that PubMatic and its executives made false or misleading statements and failed to disclose significant issues, including a top DSP buyer shifting clients to a new platform, leading to reduced ad spend and revenue [3]. - The company's positive statements regarding its business operations and prospects were deemed materially misleading and lacked a reasonable basis due to these undisclosed issues [3]. Group 2: Financial Impact - On August 11, 2025, PubMatic's CFO disclosed a reduction in ad spend from a top DSP partner, which was a significant factor affecting the company's outlook [4]. - Following this announcement, PubMatic's stock price dropped by $2.23, or 21.1%, closing at $8.34 per share on August 12, 2025, amid unusually high trading volume [4]. Group 3: Legal Proceedings - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against PubMatic is October 20, 2025 [1]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Quanex Building Products Corporation due to alleged violations of federal securities laws, particularly concerning misleading statements about the company's operational issues and financial performance [1][3]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Quanex between December 12, 2024, and September 5, 2025, to discuss their legal options [1]. - The firm has set a deadline of November 18, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Quanex [1]. Allegations Against Quanex - The complaint alleges that Quanex and its executives made false or misleading statements regarding the maintenance of tooling and equipment at the Tyman Mexico facility, which were significantly underinvested [3]. - It is claimed that the conditions of the tooling and equipment had degraded to near catastrophic levels, leading to significant costs and delays in expected benefits from the Tyman integration [3]. Financial Performance - On September 4, 2025, Quanex reported a diluted EPS of ($6.04), a significant decline from $0.77 in the prior year period, and an adjusted EBITDA of $70.30 [4]. - The company acknowledged ongoing operational issues related to the Tyman business in Mexico, which negatively impacted financial results more than anticipated during the third quarter of 2025 [4]. Earnings Call Insights - During the earnings call on September 5, 2025, CEO George Wilson highlighted that operational challenges in the Tyman facility negatively impacted EBITDA by nearly $5 million in the third quarter [5]. - Wilson noted that the issues were identified midyear and that the systems for anticipating and planning tooling repairs were severely deficient, indicating a state of underinvestment [5]. Stock Market Reaction - Following the earnings announcement, Quanex's stock price fell by $2.73, or 13.1%, closing at $18.18 per share on September 5, 2025, with unusually high trading volume [5]. - The stock continued to decline, dropping an additional $1.98, or 10.9%, to close at $16.20 per share on September 8, 2025, also on unusually heavy trading volume [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Cytokinetics, Incorporated due to misleading statements regarding the New Drug Application (NDA) for aficamten, which may have led to investor losses [1][2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Cytokinetics between December 27, 2023, and May 6, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Cytokinetics, with a deadline of November 17, 2025, for investors to seek the role of lead plaintiff [1]. Group 2: Misleading Statements - Defendants allegedly made materially false statements regarding the NDA submission timeline and FDA approval expectations for aficamten, indicating a PDUFA date of September 26, 2025, without disclosing risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) [2]. - During an earnings call on May 6, 2025, it was revealed that Cytokinetics submitted the NDA without a REMS, despite prior discussions with the FDA about safety monitoring, which misled investors about the regulatory timeline [3]. Group 3: Impact on Investors - As a result of the misleading statements, class members purchased Cytokinetics' common stock at inflated prices and incurred significant losses when the truth was disclosed [4]. - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, and any member can move to serve as lead plaintiff or remain an absent class member [5].

Core Viewpoint - A class action lawsuit has been filed against aTyr Pharma, Inc. due to misleading statements regarding the efficacy of its drug Efzofitimod, which failed to meet its primary endpoint in a clinical study [1][2][3]. Company Information - aTyr Pharma, Inc. is facing legal action for allegedly providing false and misleading information to investors about the drug Efzofitimod, particularly regarding its ability to allow patients to taper off steroid usage [2]. - The company announced disappointing results from the EFZO-FIT study on September 15, 2025, revealing that it did not meet its primary endpoint related to mean daily OSC dose reduction at week 48 [3]. Stock Performance - Following the announcement of the study results, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking a significant decline of 83.2% in just one day [4]. Legal Context - Investors who purchased aTyr's common stock between January 16, 2025, and September 12, 2025, are eligible to participate in the class action lawsuit, with a deadline to request lead plaintiff status by December 8, 2025 [4]. Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against V.F. Corporation (VFC) due to alleged violations of federal securities laws, particularly concerning misleading statements about the company's turnaround plans and the performance of the Vans brand [4][6]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in VFC between October 30, 2023, and May 20, 2025, to discuss their legal options [1][4]. - A federal securities class action has been filed against VFC, with a deadline of November 12, 2025, for investors to seek the role of lead plaintiff [4][8]. Group 2: Allegations Against VFC - The complaint alleges that VFC and its executives made false or misleading statements regarding the company's turnaround plans, particularly the need for significant reset actions to return the Vans brand to growth [6]. - The company's stock price fell approximately 15.8% in one day, from $14.43 per share on May 20, 2025, to $12.15 per share on May 21, 2025, following the disclosure of disappointing financial results [7]. Group 3: Financial Performance - VFC reported a significant decline in Vans' growth trajectory, with losses worsening from 8% in the previous quarter to 20% in the fourth quarter of fiscal 2025 [7]. - The company attributed its poor performance to deliberate actions taken to eliminate unprofitable businesses, which were not previously disclosed to investors [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action set for December 2, 2025 [3]. Group 1: Allegations Against Molina - The complaint alleges that Molina and its executives made false or misleading statements and failed to disclose material adverse facts regarding the company's medical cost trend assumptions [5]. - It is claimed that Molina was experiencing a dislocation between premium rates and medical costs, which affected its near-term growth [5]. - The financial guidance for fiscal year 2025 was likely to be cut due to these issues, and positive statements made by the defendants were misleading [5]. Group 2: Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter financial results, revealing adjusted earnings of approximately $5.50 per share, which was below prior expectations, leading to a 10.2% cut in full-year earnings guidance from at least $24.50 per share to a range of $21.50 to $22.50 [6]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share on July 7, 2025 [6]. - On July 23, 2025, Molina further slashed its full-year earnings guidance, reporting a GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year over year, and cutting its full-year adjusted earnings guidance to no less than $19.00 per diluted share [7][8]. - This led to a significant drop in Molina's stock price by $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [8].

Core Viewpoint - Molina Healthcare, Inc. is facing legal action due to allegations of making materially false and misleading statements regarding its financial outlook and medical cost trends during the specified class period [2][3]. Allegations - Molina reported Q2 2025 adjusted EPS of approximately $5.50, which was below prior expectations, leading to a 10.2% cut in its full-year earnings guidance at the midpoint [3] - The company warned that medical cost pressures would continue through the second half of the year, contributing to a decline in its stock price [3] - On July 23, 2025, Molina announced Q2 GAAP net income of $4.75 per diluted share, an 8% decrease year over year, and further reduced its full-year adjusted earnings expectations to no less than $19.00 per share due to a challenging medical cost trend environment [4] - Following this announcement, Molina's stock fell nearly 17% [4] Financial Guidance Issues - Molina's medical cost trend assumptions were found to be inaccurate [9] - There was a dislocation between premium rates and medical cost trends [9] - Near-term growth was dependent on reduced utilization of behavioral health, pharmacy, and inpatient/outpatient services [9] - Consequently, Molina's FY 2025 guidance was likely to be cut [9]

Core Viewpoint - A South Florida police pension fund and a European investment firm are seeking to be lead plaintiffs in a class-action lawsuit against Fiserv, alleging misleading statements regarding its Clover unit and significant financial losses due to share price declines [1][4]. Group 1: Lawsuit Details - The lawsuit was filed in July 2024, claiming Fiserv misled investors by not disclosing the forced migration of merchants to its Clover point-of-sale product during late 2023 to mid-2024 [4]. - The complaint names Fiserv and four executives, including current CEO Michael Lyons and former CEO Frank Bisignano, as defendants [5]. - The litigation targets investors who purchased or owned Fiserv stock between July 24, 2024, and July 22, 2025 [5]. Group 2: Financial Impact - The Hollywood police pension fund reported a loss of $1.67 million due to the decline in Fiserv shares, while Ethenea Independent Investors SA claimed a loss of $5.95 million on its investment in Fiserv [2]. - Fiserv's shares have declined by 38% this year, indicating significant financial distress for the company [6]. Group 3: Legal Process - The selection of a lead shareholder plaintiff is influenced by the size of the investor's losses and the capability of their attorneys to manage the litigation, as per the 1995 Private Securities Litigation Reform Act [3]. - The pension fund for police officers in Hollywood, Florida, manages approximately $460 million, while Ethenea Independent Investors SA manages about €2.4 billion ($2.8 billion) in assets [7].

Core Viewpoint - The article discusses ongoing legal investigations into Molina Healthcare, Inc. regarding potential violations of federal securities laws, encouraging affected investors to seek legal counsel and participate in a class action lawsuit [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare and reminds investors of the December 2, 2025 deadline to seek the role of lead plaintiff in a federal securities class action [2][4]. - The complaint alleges that Molina and its executives made false and misleading statements regarding the company's financial health and operational challenges [3][4]. Group 2: Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter financial results, revealing adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures [5]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share on July 7, 2025 [5]. - On July 23, 2025, Molina further slashed its full-year 2025 earnings guidance, reporting a GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year over year [6]. - This guidance cut represented a 13.6% reduction at the midpoint, with full-year GAAP net income guidance cut by 27% to $912 million [6][7]. - Following the second guidance cut, Molina's stock price plummeted by $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [7]. Group 3: Company Challenges - The complaint highlights several material adverse facts, including issues with medical cost trend assumptions and a dislocation between premium rates and medical costs, which have negatively impacted Molina's financial outlook [4]. - Molina's near-term growth is reportedly dependent on reduced utilization of various health services, indicating significant operational challenges [4].